Gastrointestinal (GI) complications are significant manifestations of COVID-19 and are increasingly being recognized. These complications range from severe acute pancreatitis to colitis, adding complexity to diagnosis and management. A comprehensive database search was conducted using several databases. Our inclusion criteria encompassed studies reporting severe and long-term GI complications of COVID-19. Digestive disorders were categorized into infections, inflammatory conditions, vascular disorders, structural abnormalities, other diagnoses, and undiagnosed conditions. Of the 73 studies that were selected for full-text review, only 24 met our inclusion criteria. The study highlights a broad range of gastrointestinal complications following COVID-19 infection (excluding liver complications, which are examined separately), including inflammatory conditions, such as ulcerative colitis (UC), acute pancreatitis, and multisystem inflammatory syndrome in children (MIS-C). Other GI complications were reported such as vascular disorders, including diverse thrombotic events and structural abnormalities, which ranged from bowel perforations to adhesions. Additionally, undiagnosed conditions like nausea and abdominal pain were prevalent across different studies involving 561 patients. The findings emphasize the substantial impact of COVID-19 on the GI tract. Ongoing research and monitoring are crucial to understanding the long-term effects and developing effective management strategies for these complications.
Key Points: Compared with kidney donors with uncomplicated pregnancies, donors with prior adverse pregnancy events did not have altered kidney structure at donation. Kidney function 10 years after donation was comparable between donors with and without prior adverse pregnancy outcomes. Prior adverse pregnancy outcomes do not translate into subclinical kidney injury in otherwise healthy donor candidates. Background: Hypertensive disorders of pregnancy (HDP), gestational diabetes mellitus (GDM), and preterm delivery are associated with higher long-term cardiovascular, metabolic, and kidney disease risk. Their implications for living kidney donation remain uncertain. Methods: We conducted a retrospective cohort study of 498 female living kidney donors (2000–2017) from the Mayo Clinic Living Donor Program with documented pregnancy histories, predonation computed tomography angiography, implantation kidney biopsy, and measured GFR. Donors with prior HDP ( n =45), GDM ( n =18), or preterm delivery ( n =65) were compared with donors without adverse pregnancy outcomes (APOs; n =385). Kidney morphometry, histology, and function were analyzed with adjustment for age at donation and first pregnancy, parity, and hypertension. Postdonation kidney outcomes were assessed using surveys and medical record review. Results: Donors with prior HDP and GDM had higher body mass index at donation (+7.9% and +8.9%; P = 0.006 and 0.04), whereas donors with preterm delivery had lower body mass index (−4.8%; P = 0.03) compared with donors with no APO. After adjustment, donors with HDP showed no differences in kidney volumes, biopsy features, or kidney function at donation or during follow-up. Donors with GDM had larger total and cortical kidney volumes (9.5%–10%), less arterial luminal stenosis, and higher 5-year postdonation eGFR (+15%; P = 0.03). Donors with preterm delivery had a lower risk of eGFR <45 ml/min per 1.73 m 2 (hazard ratio, 0.28; P = 0.03). Conclusions: Prior APOs were not associated with adverse kidney structure at donation or accelerated kidney function decline postdonation. These findings support that APO history alone should not preclude living kidney donation when other eligibility criteria are met.